Design: Systematic review and meta-analysis
Population: 6,264 patients with cardiovascular disease, high risk, hypertension or dyslipidaemia (9 studies)
Primary outcome: Change in systolic and diastolic blood pressure
Effect: SBP SMD −0.128 (−0.177 to −0.08); DBP SMD −0.171 (−0.233 to −0.11)

This meta-analysis included nine studies with 6,264 patients with previous myocardial infarction or stroke, high cardiovascular risk, hypertension or dyslipidaemia. It compared fixed-dose combination 'polypills' with the same classes given as separate tablets.

The polypill lowered systolic pressure (standardised mean difference −0.13) and diastolic pressure (−0.17) more than separate tablets. These are small standardised effects, and the abstract does not give them in mmHg.

The likely mechanism is adherence: fewer tablets taken more reliably. For a family physician managing a patient on four or five cardiovascular drugs, a single combination tablet is a practical simplification where an appropriate one is available. Fixed-dose combinations are widely sold in India, but their components and doses vary, and not all are evidence-based.

Consider a fixed-dose combination for patients on several cardiovascular drugs who struggle with tablet burden.
Check each component and dose of a combination product; avoid ones that lock in doses you would not choose.
Ask about missed doses before adding another antihypertensive.
Recheck blood pressure after switching to confirm control is held.

Why it matters

It supports simplifying regimens as a way of improving control, not only adding drugs.

The statistics, in plain English

A standardised mean difference of −0.13 means the average difference was about an eighth of the spread of blood pressures between patients — a small effect. It is real at the population level but may be only a few mmHg in an individual.